This systematic review evaluated the efficacy of SGLT2 inhibitors in improving hepatic steatosis, liver enzymes, glycemic control, and liver histology in patients with T2DM and NAFLD. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.